-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

Benzinga·09/01/2026 12:30:29
Listen to the news
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.